The company has two very important trials in progress and nearing data release, either release by itself should be transformative to Athersys if it's positive data. In one phase II trial Athersys is partnered with Pfizer in regards to treatment of ulcerative colitis. In a second Phase II trial in regards to treatment of ischemic stroke Athersys is partnered with University Hospitals.
Athersys also has an interesting small molecule program with the 5HT2c receptor agonist for obesity or schizophrenia. Partnership deal could unexpectedly rock the house.